Press Releases Year None2022202120202019201820172016 Gamida Cell Announces Entry into Commitment Letter with Highbridge for $25 Million Financing September 28, 2022 PDF Version View HTML Gamida Cell Announces Pricing of Approximately $20 Million Public Offering of Ordinary Shares September 28, 2022 PDF Version View HTML Gamida Cell Announces Launch of Public Offering of Ordinary Shares September 27, 2022 PDF Version View HTML Gamida Cell Appoints Abigail L. Jenkins as President and Chief Executive Officer, Bringing Broad Leadership Experience in Commercializing Innovative Therapies September 19, 2022 PDF Version View HTML Gamida Cell Presents Data Demonstrating the Impact of Transplantation with Omidubicel for Patients with Hematologic Malignancies at 2022 Cord Blood Connect Meeting September 12, 2022 PDF Version View HTML Gamida Cell Reports Second Quarter 2022 Financial Results and Provides Company Update August 15, 2022 PDF Version View HTML Gamida Cell Announces Dosing of First Patient in Company-Sponsored Phase 1/2 Study of NK Cell Therapy Candidate GDA-201 August 10, 2022 PDF Version View HTML Gamida Cell Announces the Date of Its Second Quarter 2022 Financial Results and Webcast August 8, 2022 PDF Version View HTML Gamida Cell Announces FDA Acceptance of Biologics License Application for Omidubicel with Priority Review August 1, 2022 PDF Version View HTML Gamida Cell to Present Corporate Highlights at the JMP Securities Life Sciences Conference June 13, 2022 PDF Version View HTML Pagination First page « first Previous page ‹ previous Page 1 Current page 2 Page 3 Page 4 Page 5 Next page next › Last page last » Displaying 11 - 20 of 41
